News

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
'Taking A GLP-1 Has Made Me Hopeful About My Health For the First Time'
She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...
What’s Happening With LLY Stock?
LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...
BioSpace21h
WHO Leaning Toward Adding Obesity Drugs for Adults to Essential Medicines List: Reuters
In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...
Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade'
But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...
WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%
WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli ...
Zacks.com on MSN1d
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...
Eli Lilly stock slips despite earnings beat, reaffirmed 2025 guidance
Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.